Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation Serial intravascular ultrasound analysis from the sirius trial by Sonoda, Shinjo et al.
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OBJECTIVES We assessed the predictive value of minimum stent area (MSA) for long-term patency of
sirolimus-eluting stents (SES) implantation compared to bare metal stents (BMS).
BACKGROUND Although MSA is a consistent predictor of in-stent restenosis, its predictive value in BMS is
still limited because of biologic variability in the restenosis process.
METHODS From the SIRolImUS (SIRIUS) trial, 122 cases (SES: 72; BMS: 50) with complete serial
intravascular ultrasound (IVUS) (baseline and 8-month follow-up) were analyzed. Postpro-
cedure MSA and follow-up minimum lumen area (MLA) were obtained. Based on previous
physiologic studies, adequate stent patency at follow-up was defined as MLA 4 mm2.
RESULTS In both groups, a significant positive correlation was observed between baseline MSA and
follow-up MLA (SES: p  0.0001, BMS: p  0.0001). However, SES showed higher
correlation than BMS (0.8 vs. 0.65) with a higher regression coefficient (0.92 vs. 0.59). The
sensitivity and specificity curves identified different optimal thresholds of MSA to predict
adequate follow-up MLA: 5 mm2 for SES and 6.5 mm2 for BMS. The positive predictive
values with these cutoff points were 90% and 56%, respectively.
CONCLUSIONS In this SIRIUS IVUS substudy, SES reduced both biologic variability and restenosis,
resulting in increased predictability of long-term stent patency with postprocedure MSA. In
addition, SES had a considerably lower optimal MSA threshold compared to BMS. (J Am
Coll Cardiol 2004;43:1959–63) © 2004 by the American College of Cardiology Foundations
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pespite the widespread use of intracoronary stents, in-stent
estenosis remains a major clinical problem (1,2). Intravas-
ular ultrasound (IVUS) permits detailed cross-sectional
maging of the coronary arteries and has been used to
ptimize stent deployment. Several studies have demon-
trated that IVUS-derived lumen dimension after stent
eployment (minimum stent area [MSA]) is a consistent
redictor of in-stent restenosis (3,4). In bare metal stents
BMS), however, the predictive value of IVUS is still
imited because of biologic variability in the in-stent reste-
osis process. Current treatment with anti-proliferative
rug-coated stents appears to be a promising approach to
echanically remodeling target lesions and biologically
educing neointimal hyperplasia (5,6). Initial clinical appli-
ations of sirolimus-eluting stents (SES) in single primary
esions were shown to be safe and feasible in preventing
eointimal hyperplasia, with complete abolition of resteno-
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Manuscript received November 4, 2003; revised manuscript received January 8,a004, accepted January 27, 2004.is (7,8). These results may indicate consistent efficacy of
rug-eluting stents irrespective of degree of biologic activity
patient, lesion profile, and risk factors) in each lesion. The
im of this study was to report the impact of the final stent
imension (as assessed by IVUS) on long-term results in
ES compared to BMS.
ETHODS
tudy population and design. The SIRIUS trial is a U.S.
ulticenter randomized double-blind study of the
irolimus-eluting stent to evaluate the safety and efficacy of
he sirolimus-eluting Bx-Velocity stent compared with a
MS (uncoated metal Bx-Velocity stent) in the prevention
f in-stent restenosis (Cordis Corp., Johnson and Johnson,
arren, New Jersey) (9).
This study was specifically designed to include a more
estenosis-prone de novo native coronary lesion subset than
ither the RAndomized study with the sirolimus-eluting
Elocity balloon-expandable stent in the treatment of
atients with de novo native coronary artery Lesions
RAVEL) (10) or the First in Man trial (7). The institu-
ional review board at all investigational sites approved the
tudy protocol, and written informed consent was obtained
rom all patients. We studied an IVUS subgroup of 122
atients (SES: 72; BMS: 50) with complete serial IVUS
nalyses from the SIRIUS trial.
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Optimal MSA After Sirolimus-Eluting Stents June 2, 2004:1959–63VUS analysis. All cineangiograms and IVUS images were
ndependently analyzed at independent core laboratories
lind to the treatment protocol. Serial angiography and
VUS were performed after intracoronary administration of
itroglycerin immediately after the procedure and at eight-
onth follow-up. Quantitative IVUS analysis was per-
ormed using commercially available planimetry software
TapeMeasure/EchoPlaque, Indec System, Mountain
iew, California) according to previously validated and
ublished protocols. Vessel, stent, lumen, and neointimal
rea were computed for the stented segment. Postprocedure
SA, eight-month follow-up minimum lumen area
MLA), and neointimal area at the MLA site were ob-
ained. Percent neointimal area was calculated as neointimal
rea divided by stent area. Percent stent expansion was
alculated as MSA divided by average reference lumen area.
ased on previous clinical studies, adequate stent patency at
ollow-up was defined as MLA 4 mm2 (11).
tatistical analysis. Statistical analysis was performed with
tatView 5.0 software (SAS Institute, Cary, North Caro-
ina). Quantitative data are presented as mean  SD and
ualitative data are presented as frequencies. Comparison
as performed with unpaired Student t test and chi-square
est. Linear regression analysis and Bland-Altman analysis
ere performed to evaluate the correlation between post-
rocedure MSA and follow-up MLA. A value of p  0.05
as considered statistically significant. Optimal MSA
hresholds were determined on the basis of the same
ensitivity and specificity values because the availability of a
able 1. Clinical and Procedural Characteristics
BMS
(n  50)
SES
(n  72) p Value
ge (yrs) 61.8  9.9 59.0  9.9 0.13
ale (%) 68 76 0.31
isk factors (%)
Hypertension 60 67 0.45
Diabetes 32 25 0.40
Hyperlipidemia 68 71 0.74
Smoking 28 31 0.76
essel treated
LAD/RCA/LCX (%) 42/30/28 44/31/25 0.93
eference lumen
diameter (mm)
2.80  0.47 2.76  0.45 0.61
esion length (mm) 15.65  5.11 14.14  4.85 0.10
inal balloon size (mm) 3.28  0.53 3.01  0.40 p  0.05
aximum inflation
pressure (atm)
16.6  2.6 17.1  2.9 0.34
MS  bare metal stents; LAD  left anterior descending; LCX  left circumflex;
Abbreviations and Acronyms
BMS  bare metal stents
IVUS  intravascular ultrasound
MLA  minimum lumen area
MSA  minimum stent area
SES  sirolimus-eluting stentsTCA  right coronary artery; SES  sirolimus-eluting stents.etter sensitivity through a decreased cutoff point would
esult in a worse specificity. In addition, we analyzed the
oints of intersection of both the sensitivity and specificity
urves as optimal cutoff points for predicting adequate
ollow-up MLA.
ESULTS
aseline characteristics of cases used in this analysis were
omparable to the overall enrolled patient population. Base-
ine lesion and procedural characteristics were similar in
oth groups except for the final balloon size (Table 1).
uantitative coronary angiography and IVUS data at post-
rocedure are shown in Table 2. The MSA at postprocedure
as 5.8  1.8 mm2 in SES and 6.0  2.1 mm2 in BMS (p
NS). The MLA at eight-month follow-up was 5.3  2.0
m2 in SES and 3.6  1.9 mm2 in BMS (p  0.0001).
irolimus-eluting stents significantly reduced late lumen
oss compared with BMS (SES: 0.6  1.2 mm2, BMS: 2.4
1.6 mm2, p  0.0001) because of overall reduction of
eointimal tissue growth at the site of MLA (% neointimal
rea, SES: 8.5  13.4%, BMS: 36.2  16.9%, p  0.0001).
n addition, the distribution curves indicated significantly
educed variability in neointimal tissue growth among the
ES cases (Fig. 1).
Although a highly significant positive correlation was
bserved between postprocedure MSA and follow-up MLA
n both groups (SES: p  0.0001, BMS: p  0.0001), SES
howed higher correlation than BMS (0.80 vs. 0.65), with a
igher regression coefficient (0.92 vs. 0.59) (Fig. 2). The
ensitivity and specificity curves identified different optimal
hresholds of MSA to predict adequate follow-up MLA: 5.0
m2 for SES and 6.5 mm2 for BMS (Fig. 3). The positive
redictive values with these cutoff points were 90% in SES
nd 56% in BMS, respectively (Table 3).
The diagnostic value of absolute MSA was then com-
ared to that of relative parameter to the reference artery
MSA divided by mean reference vessel area [REFVA]).
able 2. Angiographic and IVUS Measurements at
ostprocedure
BMS
(n  50)
SES
(n  72) p Value
oronary angiography
Reference lumen
diameter (mm)
2.80  0.47 2.76  0.45 0.61
Minimum lumen
diameter (mm)
2.72  0.44 2.72  0.38 0.97
Diameter stenosis (%) 5.1  7.1 3.3  7.1 0.18
VUS
Reference lumen area
(mm2)
7.32  2.52 7.89  3.69 0.34
Minimum stent area
(mm2)
6.03  2.15 5.84  1.76 0.59
% stent expansion 84.4  19.9 80.2  24.6 0.32
MS bare metal stents; IVUS intravascular ultrasound; SES sirolimus-eluting
tents.he receiver operating characteristic curves showed that
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June 2, 2004:1959–63 Optimal MSA After Sirolimus-Eluting Stentsbsolute MSA was more diagnostic than MSA/REFVA
Fig. 4). In addition, in the subset of 66 patients (SES: 41;
MS: 25) with lesions in small coronary arteries (reference
essel diameter of 2.8 mm as measured by quantitative
oronary angiography), smaller optimal thresholds of MSA
o predict adequate follow-up MLA were obtained (SES:
.5 mm2; BMS: 6 mm2).
ISCUSSION
onventional stent era. The guiding principle of stent
eployment was to achieve the largest lumen area possible in
ach lesion. This paradigm, so-called bigger-is-better, was
ased upon a theory verified in several clinical studies:
lthough late lumen loss increases with initial lumen gain,
arger postprocedure lumen generally results in greater net
umen outcome at follow-up because of the relatively
niform late loss index or “tax rate” (0.44 to 0.47) across
onventional stents (12,13). However, the degree of biologic
esponse to the acute mechanical injury by stent implanta-
ion and/or sustained stimuli from the rigid metal struts,
amely the amount of neointimal proliferation, follows a
ear-Gaussian distribution (14). As seen in the BMS group
f the present study, this biologic variability significantly
imits the ability to predict the probability of stent patency
or the individual patient based on the mechanical param-
igure 2. Relationship between postprocedural minimum stent area (MSA
howed higher correlation than bare metal stents (BMS) (0.80 vs. 0.65) w
igure 1. Distribution of percentage of neointimal area (%NA, neoin
irolimus-eluting stents (SES) (left) and bare metal stents (BMS) (right).f SES, irrespective of variable degrees of biological activity in each individualter alone (15–17). For this reason, achieving the largest
ostprocedure lumen is further underscored to ensure the
reatest “safety margin” for unexpectedly large neointimal
yperplasia that can occasionally follow conventional
tenting.
rug-eluting stent era. In the current study, however, the
verall amount of late loss in SES was less than BMS
ecause of significant suppression of neointimal tissue
rowth. Furthermore, a tighter positive correlation was
bserved between baseline MSA and follow-up MLA in
ES than in BMS. Hence, SES had a considerably lower
ptimal MSA threshold (5.0 mm2) compared to BMS (6.5
m2) to predict eight-month stent patency. On one hand,
n MSA of 5.0 mm2 discriminates between adequate versus
nadequate lumens at follow-up, indicating that a smaller
SA may be clinically adequate post-SES compared with
MS. On the other hand, this MSA has a specificity of
3%, indicating that an inadequate MSA determines most
f the cases of restenosis post-SES. Thus, whereas a smaller
SA may be acceptable post-SES, SES underexpansion
an result in restenosis.
mall vessel subset. The acute results of stenting in small
oronary arteries are variable (18), and the long-term
utcomes are worse compared to the stenting of large
oronary arteries (19). Proportional parameter to the refer-
follow-up minimum lumen area (MLA). Sirolimus-eluting stents (SES)
higher regression coefficient (0.92 vs. 0.59), indicating consistent efficacy
l area/stent area) at the site of follow-up minimum lumen area for) and
ith atimalesion.
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Optimal MSA After Sirolimus-Eluting Stents June 2, 2004:1959–63nce vessel size may potentially be of use, especially in
maller coronary arteries (15). However, absolute MSA was
onsidered to be more predictive for long-term stent pa-
ency compared to MSA/REFVA in the current study.
espite the small number of this subset, the current study
lso suggested optimal MSA thresholds of 4.5 mm2 in SES
nd 6.0 mm2 in BMS in small coronary arteries. This
hreshold in BMS (6.0 mm2) was consistent with previous
tudy in small vessels (20).
linical implications. These observations have potentially
mportant clinical implications. In conventional stenting,
eep vessel wall injury resulting from aggressive stent
xpansion may contribute to greater neointimal prolifera-
ion following larger acute lumen gain. Nevertheless, the
igger-is-better strategy is critically important owing to the
npredictability of biologic response in individual lesions. In
ontrast, drug-eluting stents may not require as large a
afety margin for biologic variability as conventional stents
nd, therefore, aggressive dilation to achieve the largest
umen area possible may no longer provide additional
linical benefit. The higher predictability of follow-up stent
imensions may also facilitate “adequate” deployment of
rug-eluting stents to minimize vessel wall injury and
ubsequent neointimal proliferation and/or vessel shrinkage
t stent edges.
tudy limitations. First, the results obtained are limited to
essel diameters and stent lengths used in the SIRIUS trial.
hese findings should be confirmed in real-world registries
igure 3. The sensitivity and specificity curves identified different optim
inimum lumen area (MLA): 5.0 mm2 for sirolimus-eluting stents (SES)
etter longer-term outcome with an “optimized” lower MSA threshold. T
Table 3. Diagnostic Values of Optimal Thresh
Optimal
Threshold PPV
SES (n  72) 5.0 mm2 90%
BMS (n  50) 6.5 mm2 56%BMS  bare metal stents; PPV  positive predictive value; SES hat may enroll more complex lesions in smaller vessels.
econd, data analysis to determine follow-up MLA was
estricted to the stented segment, given that the cause of
tent edge restenosis is complex. Previous studies have
ndicated several periprocedural predictors of subsequent
tent edge restenosis. Injury from the stent deployment
alloon in the adjacent area and postprocedural cross-
ectional narrowing of the contiguous stent margins tend to
rigger stent edge restenosis (21). Natural lumen tapering at
he stent margins may cause stent edge restenosis (22).
urthermore, limited diffusion of drug in the stent margins
ay also trigger stent edge restenosis. The stent edge issue
as considered beyond the scope of this study. Third,
omplete serial IVUS quantitative analysis was available in
nly 122 cases and thus selection bias may have been
resent. In fact, in baseline patient/lesion and procedural
haracteristics, there was a significant difference in the final
alloon size, which was significantly larger in those receiv-
ng BMS. This difference, however, would tend to bias our
esults in a direction opposite from that shown in the final
utcome.
onclusions. In this SIRIUS IVUS substudy, SES re-
uced biologic variability and increased predictability of
ong-term stent patency with postprocedure MSA. In ad-
ition, SES had a considerably lower optimal MSA thresh-
ld compared to BMS. Overall, stent underexpansion
hould be avoided because MSA5.0 mm2 was responsible
or the majority of SES restenosis.
resholds of minimum stent area (MSA) to predict adequate follow-up
.5 mm2 for bare metal stents (BMS). Sirolimus-eluting stents may achieve
les  sensitivity; circles  specificity.
or SES and BMS
Sensitivity Specificity Accuracy
76% 83% 78%
63% 78% 73%al th
and 6
riangold fsirolimus-eluting stents.
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